Liver News and Research

RSS

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Research: Single episode of binge drinking can have negative health effects

It only takes one time. That's the message of a new study by scientists at the University of Massachusetts Medical School on binge drinking. Their research found that a single episode of binge drinking can have significant negative health effects resulting in bacteria leaking from the gut, leading to increased levels of toxins in the blood.

16 May 2014

New dual-pronged approach for treating Niemann-Pick type C disease

By studying nerve and liver cells grown from patient-derived induced pluripotent stem cells (iPSCs), Whitehead Institute researchers have identified a potential dual-pronged approach to treating Niemann-Pick type C (NPC) disease, a rare but devastating genetic disorder.

16 May 2014

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions.

16 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Researchers use natural molecule to treat type 2 diabetes

Researchers at the Universit- Laval Faculty of Medicine, the Quebec Heart and Lung Institute Research Center, and the Institute of Nutrition and Functional Foods have discovered a natural molecule that could be used to treat insulin resistance and type 2 diabetes.

13 May 2014

Esaote gets FDA clearance to market Virtual Navigator fusion imaging technology for ultrasound

Esaote North America announced today that it has received FDA clearance to market and sell its Virtual Navigator fusion imaging technology for ultrasound.

12 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

Researchers from Italy confirm that urinary ethyl glucuronide (uEtG) accurately detects alcohol consumption in liver transplant candidates and recipients.

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Triple therapy shows promise for severe PAH

Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.

7 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

Perfusion system at room temperature preserves and improves metabolic function of donor livers

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine (CEM) and the MGH Transplant Center has the potential to increase both the supply and the quality of donor organs for liver transplantation.

7 May 2014

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Snacking linked with abdominal fat and fatty liver

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).

7 May 2014

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

While many parents-to-be are aware that the health of their baby starts before they've actually arrived into the world, recent research reveals that "harm" (i.e., tobacco smoke, dirty air, poor nutrition, even preeclampsia) may not present itself disease-wise until well into adulthood or when a second harmful "hit" triggers the individual's susceptibility.

6 May 2014

Liver News and Research

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Research: Single episode of binge drinking can have negative health effects

New dual-pronged approach for treating Niemann-Pick type C disease

U.S. urges daily pill for those at risk of AIDS

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Researchers use natural molecule to treat type 2 diabetes

Esaote gets FDA clearance to market Virtual Navigator fusion imaging technology for ultrasound

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Triple therapy shows promise for severe PAH

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Perfusion system at room temperature preserves and improves metabolic function of donor livers

Cumberland launches new Vaprisol product

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Snacking linked with abdominal fat and fatty liver

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News